A European position statement on the current situation and unmet needs in cGvHD

A European position statement, providing a comprehensive synthesis of the evolving biology, epidemiology, diagnosis, and management of chronic graft-versus-host disease (cGvHD), was published in Bone Marrow Transplantation by Malard et al. The key aims of this statement were to highlight heterogeneity in disease definitions and management, to outline harmonization strategies and research priorities, and to propose collaborative initiatives for optimizing cGvHD diagnosis and treatment. 

Key data: cGvHD arises from a cascade of immune dysregulation, disordered tissue repair, and progressive fibrotic remodeling that together shape its clinical heterogeneity and chronicity. Although recent therapeutic innovations have expanded options beyond corticosteroids, treatment responses remain variable and organ-specific approaches are lacking. Advancing the field depends on standardized diagnostic and response criteria, improved biomarkers for risk stratification and disease monitoring, and refined preclinical models. Early identification of at-risk patients, optimized prophylaxis, and sequencing of therapies should be guided by robust biological correlates rather than empirical practice. Integrating patient-reported outcomes (PROs) and real-world data will also be critical to ensure that therapeutic advances translate into meaningful benefits for patients. 

Key learning: Despite persistent unmet needs in the management of cGvHD, a collaborative approach centered around individualized therapy, standardized clinical assessment and research, and integrated supportive care is key to improving patient outcomes.